Abstract
SUMMARY Metastatic breast cancer is considered incurable, with a 5-year survival of approximately 23%. However, sequential chemotherapy regimens produce clinical benefit for patients, including prolonged progression-free and overall survival times. Eribulin is a convenient (<5 min infusion) and novel treatment that has shown activity and efficacy and tolerability in advanced breast cancer patients in Phase II and Phase III trials. Eribulin has also shown encouraging results as first-line treatment, either alone in patients with HER2- disease or in combination with trastuzumab in patients with HER2+ disease, in Phase II trials.
Subject
Radiology, Nuclear Medicine and imaging,Oncology
Reference41 articles.
1. Cancer Statistics, 2010
2. Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009
3. National Cancer Institute. SEER Stat fact sheets: breast. http://seer.cancer.gov/statfacts/html/breast.html.
4. American Cancer Society. Breast cancer facts & figures 2011–2012. www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-030975.pdf.
5. Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant
Therapy
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献